The stock of Design Therapeutics Inc (DSGN) has seen a -17.75% decrease in the past week, with a -20.83% drop in the past month, and a 3.15% flourish in the past quarter. The volatility ratio for the week is 10.53%, and the volatility levels for the past 30 days are at 8.89% for DSGN. The simple moving average for the past 20 days is -17.99% for DSGN’s stock, with a 5.48% simple moving average for the past 200 days.
Is It Worth Investing in Design Therapeutics Inc (NASDAQ: DSGN) Right Now?
DSGN has 36-month beta value of 1.83. Analysts have mixed views on the stock, with 0 analysts rating it as a “buy,” 1 as “overweight,” 2 as “hold,” and 0 as “sell.”
The public float for DSGN is 31.41M, and currently, short sellers hold a 8.59% ratio of that float. The average trading volume of DSGN on January 10, 2025 was 166.09K shares.
DSGN) stock’s latest price update
The stock price of Design Therapeutics Inc (NASDAQ: DSGN) has dropped by -14.27 compared to previous close of 5.92. Despite this, the company has seen a fall of -17.75% in its stock price over the last five trading days. globenewswire.com reported 2024-11-13 that CARLSBAD, Calif., Nov. 13, 2024 (GLOBE NEWSWIRE) — Design Therapeutics, Inc. (Nasdaq: DSGN), a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases, today announced that management will participate in the following upcoming investor conferences:
Analysts’ Opinion of DSGN
Many brokerage firms have already submitted their reports for DSGN stocks, with Piper Sandler repeating the rating for DSGN by listing it as a “Overweight.” The predicted price for DSGN in the upcoming period, according to Piper Sandler is $12 based on the research report published on May 07, 2024 of the previous year 2024.
Piper Sandler, on the other hand, stated in their research note that they expect to see DSGN reach a price target of $6, previously predicting the price at $42. The rating they have provided for DSGN stocks is “Neutral” according to the report published on November 14th, 2023.
Wedbush gave a rating of “Neutral” to DSGN, setting the target price at $6 in the report published on August 15th of the previous year.
DSGN Trading at -15.81% from the 50-Day Moving Average
After a stumble in the market that brought DSGN to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -34.68% of loss for the given period.
Volatility was left at 8.89%, however, over the last 30 days, the volatility rate increased by 10.53%, as shares sank -22.04% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -6.71% lower at present.
During the last 5 trading sessions, DSGN fell by -17.75%, which changed the moving average for the period of 200-days by +33.55% in comparison to the 20-day moving average, which settled at $6.19. In addition, Design Therapeutics Inc saw -17.75% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at DSGN starting from Prasad Deepa, who sale 3,806 shares at the price of $6.27 back on Dec 18 ’24. After this action, Prasad Deepa now owns 20,000 shares of Design Therapeutics Inc, valued at $23,864 using the latest closing price.
William Arsani, the Director of Design Therapeutics Inc, sale 814,874 shares at $4.25 during a trade that took place back on Aug 09 ’24, which means that William Arsani is holding 0 shares at $3,463,214 based on the most recent closing price.
Stock Fundamentals for DSGN
Current profitability levels for the company are sitting at:
- -72.57 for the present operating margin
- 0.48 for the gross margin
The net margin for Design Therapeutics Inc stands at -57.02. The total capital return value is set at -0.24. Equity return is now at value -17.78, with -17.02 for asset returns.
Currently, EBITDA for the company is -66.33 million with net debt to EBITDA at 0.46. When we switch over and look at the enterprise to sales, we see a ratio of 309.72. The liquidity ratio also appears to be rather interesting for investors as it stands at 34.61.
Conclusion
To put it simply, Design Therapeutics Inc (DSGN) has had a mixed performance in recent times. Analysts have a mixed opinion on the stock, with some rating it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
